| 000 | 01788 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514193552.0 | ||
| 264 | 0 | _c20050131 | |
| 008 | 200501s 0 0 eng d | ||
| 022 | _a0268-3369 | ||
| 024 | 7 |
_a10.1038/sj.bmt.1704609 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aInbal, A | |
| 245 | 0 | 0 |
_aAssessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _cSep 2004 |
||
| 300 |
_a459-63 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xadministration & dosage |
| 650 | 0 | 4 | _aBlood Coagulation |
| 650 | 0 | 4 |
_aCD40 Ligand _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHematologic Neoplasms _xepidemiology |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylenetetrahydrofolate Reductase (NADPH2) _xgenetics |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aThrombosis _xblood |
| 650 | 0 | 4 | _aTransplantation Conditioning |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 700 | 1 | _aLubetsky, A | |
| 700 | 1 | _aShimoni, A | |
| 700 | 1 | _aDardik, R | |
| 700 | 1 | _aSela, B A | |
| 700 | 1 | _aEskaraev, R | |
| 700 | 1 | _aLevi, I | |
| 700 | 1 | _aTov, N S | |
| 700 | 1 | _aNagler, A | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 34 _gno. 5 _gp. 459-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bmt.1704609 _zAvailable from publisher's website |
| 999 |
_c14951036 _d14951036 |
||